Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adenosine Deaminase Severe Combined Immune Deficiency: early-phase trial registry
1 of 1 indexed Adenosine Deaminase Severe Combined Immune Deficiency trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
Adenosine Deaminase Severe Combined Immune Deficiency: 1 US clinical trial tracked, 1 recruiting.
Adenosine Deaminase Severe Combined Immune Deficiency is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, Los Angeles, running 1 of these trials.
Enrollment posture brief
Registry condition adenosine-deaminase-severe-combined-immune-deficiency
OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Adenosine Deaminase Severe Combined Immune Deficiency lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adenosine Deaminase Severe Combined Immune Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adenosine Deaminase Severe Combined Immune Deficiency is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Adenosine Deaminase Severe Combined Immune Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adenosine Deaminase Severe Combined Immune Deficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adenosine Deaminase Severe Combined Immune Deficiency page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Adenosine Deaminase Severe Combined Immune Deficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of California, Los Angeles sponsors the most Adenosine Deaminase Severe Combined Immune Deficiency trials on record, review their full trial history before evaluating a specific study. See University of California, Los Angeles's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adenosine Deaminase Severe Combined Immune Deficiency condition card totals 1 registered trials; most-linked intervention A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.